drug
Sylatron
Marketedupdated 3mo agoby $MRK Merck & Co., Inc.
Approvedcommunity read0 votes
indications
investigational
Melanoma
all catalysts(0)
nothing on the calendar yet
Trials studying Sylatron
- phase3A Clinical Trial of Bomedemstat in Participants With Polycythemia Vera (MK-3543-025)
- phase3Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance
- phase1Ropeginterferon in Patients w/Cutaneous T-Cell Lymphoma (CTCL)
- phase2Ropeginterferon Alfa-2b for the Treatment of Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes and Chronic Myelomonocytic Leukemia
- phase3Efficacy and Safety of MP-424, Peginterferon Alfa-2b, and Ribavirin in Patients With Chronic Hepatitis C Who Relapsed After Previous Interferon Based Therapy
- phase3Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Relapser Genotype 2 Hepatitis C Infected Patients
- phase3Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Non-responder Genotype 2 Hepatitis C Infected Patients
- phase3Efficacy and Safety of MP-424/Peginterferon Alfa-2b/Ribavirin Combination in Treatment-Naïve Patients With Chronic Hepatitis C
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 31m ago
Found something off?
comments(0)
5-min edit window · permanent after that